Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	88.67M -28.7%
Revenue (ttm)	9.47M +26.1%
Net Income	-14.96M
EPS	-0.05
Shares Out	305.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,190
Open	0.2850
Previous Close	0.2800
Day's Range	0.2800 - 0.3000
52-Week Range	0.2650 - 0.7300
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure inf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In fiscal year 2026, Recce Pharmaceuticals's revenue was 9.47 million, an increase of 26.06% compared to the previous year's 7.51 million. Losses were -14.96 million, -30.18% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error